We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
26
PUT
Roivant Sciences
ROIV
$24.5B
$6.92M 1.19%
318,700
+18,700
+6% +$369K
OCUL icon
27
CALL
Ocular Therapeutix
OCUL
$1.79B
$6.62M 1.14%
545,200
+408,500
+299% +$4.96M
ZYME icon
28
CALL
Zymeworks
ZYME
$1.61B
$6.33M 1.09%
240,600
+44,100
+22% +$962K
CRSP icon
29
CALL
CRISPR Therapeutics
CRSP
$4.73B
$5.91M 1.02%
112,700
+700
+0.6% +$41.9K
CAPR icon
30
PUT
Capricor Therapeutics
CAPR
$223M
$5.77M 0.99%
+200,000
New +$2.61M
BBIO icon
31
BridgeBio Pharma
BBIO
$15.7B
$5.35M 0.92%
+70,000
New +$4.59M
UTHR icon
32
United Therapeutics
UTHR
$25.8B
$4.87M 0.84%
+10,000
New +$4.66M
CORT icon
33
PUT
Corcept Therapeutics
CORT
$12.4B
$4.69M 0.81%
134,800
+108,300
+409% +$8.51M
COGT icon
34
Cogent Biosciences
COGT
$6.65B
$4.68M 0.81%
131,852
+34,039
+35% +$957K
CAPR icon
35
Capricor Therapeutics
CAPR
$223M
$4.56M 0.79%
+158,075
New +$2.06M
VRTX icon
36
Vertex Pharmaceuticals
VRTX
$121B
$4.53M 0.78%
+10,000
New +$4.31M
ANIP icon
37
ANI Pharmaceuticals
ANIP
$1.8B
$4.21M 0.73%
53,354
+21,954
+70% +$1.9M
REGN icon
38
CALL
Regeneron Pharmaceuticals
REGN
$78.5B
$3.86M 0.66%
+5,000
New +$3.4M
TGTX icon
39
TG Therapeutics
TGTX
$7.96B
$3.68M 0.63%
123,283
+62,535
+103% +$2.04M
BIOA
40
BioAge Labs
BIOA
$402M
$3.59M 0.62%
+271,164
New +$2.4M
CORT icon
41
Corcept Therapeutics
CORT
$12.4B
$3.39M 0.58%
+97,445
New +$7.65M
MNKD icon
42
CALL
MannKind Corp
MNKD
$1.21B
$3.13M 0.54%
552,300
-487,200
-47% -$2.68M
RXRX icon
43
CALL
Recursion Pharmaceuticals
RXRX
$1.59B
$3.03M 0.52%
741,900
+43,500
+6% +$215K
TGTX icon
44
PUT
TG Therapeutics
TGTX
$7.96B
$2.98M 0.51%
+100,000
New +$3.27M
TENX icon
45
Tenax Therapeutics
TENX
$363M
$2.96M 0.51%
+243,170
New +$2.12M
RVMD icon
46
Revolution Medicines
RVMD
$39.9B
$2.95M 0.51%
37,020
-22,059
-37% -$1.45M
NTLA icon
47
PUT
Intellia Therapeutics
NTLA
$1.49B
$2.85M 0.49%
+316,900
New +$4.36M
GOSS icon
48
CALL
Gossamer Bio
GOSS
$82.9M
$2.72M 0.47%
877,100
+52,300
+6% +$149K
NVO
49
PUT
Novo Nordisk
NVO
$208B
$2.7M 0.47%
53,100
-46,900
-47% -$2.4M
ABUS icon
50
CALL
Arbutus Biopharma
ABUS
$857M
$2.64M 0.45%
548,600
+32,300
+6% +$145K
1
2
3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.